盐酸米托蒽醌脂质体注射液治疗外周T细胞淋巴瘤中国专家共识

Chinese expert consensus on mitoxantrone hydrochloride liposome injection in treatment of peripheral T-cell lymphoma

盐酸米托蒽醌脂质体注射液是一种新型蒽环类药物脂质体制剂,于2022年1月在我国获批上市,用于既往至少经过一线标准治疗的复发或难治外周T细胞淋巴瘤成年患者。自上市以来,多项临床研究显示含盐酸米托蒽醌脂质体注射液方案治疗外周T细胞淋巴瘤具有良好的效果,可改善患者预后。为进一步规范盐酸米托蒽醌脂质体注射液在外周T细胞淋巴瘤治疗中的临床应用,专家组成员结合盐酸米托蒽醌脂质体注射液应用现状及临床研究数据,制定了本共识,供临床医师参考。

Mitoxantrone hydrochloride liposome injection,a novel anthracycline liposome preparation,has been approved in China in January 2022 for adult patients with relapsed or refractory peripheral T-cell lymphoma after at least one prior standard treatment.Since its launch,several clinical studies have demonstrated that the mitoxantrone hydrochloride liposome injection-containing regimens are effective in the treatment of PTCL,and can improve the prognosis of patients.To further standardize the clinical application of mitoxantrone hydrochloride liposome injection in treatment of peripheral T-cell lymphoma,the members of the expert group developed this consensus based on the current application status and clinical research data of mitoxantrone hydrochloride liposome injection,providing valuable references for clinicians.